- Home
- ALXO vs GAME Comparison
ALXO vs GAME Comparison
Compare ALXO & GAME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- GAME
- Stock Information
- Founded
- ALXO 2015
- GAME 2011
- Country
- ALXO United States
- GAME United States
- Employees
- ALXO N/A
- GAME N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- GAME
- Sector
- ALXO Health Care
- GAME
- Exchange
- ALXO Nasdaq
- GAME Nasdaq
- Market Cap
- ALXO 24.0M
- GAME 27.2M
- IPO Year
- ALXO 2020
- GAME 2009
- Fundamental
- Price
- ALXO $0.56
- GAME $0.90
- Analyst Decision
- ALXO Strong Buy
- GAME Strong Buy
- Analyst Count
- ALXO 6
- GAME 3
- Target Price
- ALXO $3.30
- GAME $3.67
- AVG Volume (30 Days)
- ALXO 456.6K
- GAME 440.4K
- Earning Date
- ALXO 05-08-2025
- GAME 05-15-2025
- Dividend Yield
- ALXO N/A
- GAME N/A
- EPS Growth
- ALXO N/A
- GAME N/A
- EPS
- ALXO N/A
- GAME N/A
- Revenue
- ALXO N/A
- GAME $99,579,536.00
- Revenue This Year
- ALXO N/A
- GAME $14.34
- Revenue Next Year
- ALXO N/A
- GAME $24.00
- P/E Ratio
- ALXO N/A
- GAME N/A
- Revenue Growth
- ALXO N/A
- GAME 77.06
- 52 Week Low
- ALXO $0.41
- GAME $0.50
- 52 Week High
- ALXO $10.97
- GAME $1.43
- Technical
- Relative Strength Index (RSI)
- ALXO 59.08
- GAME 67.49
- Support Level
- ALXO $0.44
- GAME $0.78
- Resistance Level
- ALXO $0.48
- GAME $0.98
- Average True Range (ATR)
- ALXO 0.05
- GAME 0.08
- MACD
- ALXO 0.02
- GAME 0.02
- Stochastic Oscillator
- ALXO 99.16
- GAME 76.41
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.